Logo image of VTAK

CATHETER PRECISION INC (VTAK) Stock Fundamental Analysis

NYSEARCA:VTAK - NYSE Arca - US74933X6094 - Common Stock - Currency: USD

0.2264  +0 (+0.8%)

Premarket: 0.4686 +0.24 (+106.98%)

Fundamental Rating

2

Taking everything into account, VTAK scores 2 out of 10 in our fundamental rating. VTAK was compared to 188 industry peers in the Health Care Equipment & Supplies industry. VTAK has a bad profitability rating. Also its financial health evaluation is rather negative. VTAK shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VTAK had negative earnings in the past year.
In the past year VTAK has reported a negative cash flow from operations.
In the past 5 years VTAK always reported negative net income.
In the past 5 years VTAK always reported negative operating cash flow.
VTAK Yearly Net Income VS EBIT VS OCF VS FCFVTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

VTAK has a worse Return On Assets (-93.43%) than 79.26% of its industry peers.
VTAK has a worse Return On Equity (-292.71%) than 80.85% of its industry peers.
Industry RankSector Rank
ROA -93.43%
ROE -292.71%
ROIC N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
VTAK Yearly ROA, ROE, ROICVTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With an excellent Gross Margin value of 90.02%, VTAK belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTAK Yearly Profit, Operating, Gross MarginsVTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTAK has more shares outstanding than it did 1 year ago.
VTAK has a worse debt/assets ratio than last year.
VTAK Yearly Shares OutstandingVTAK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
VTAK Yearly Total Debt VS Total AssetsVTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

VTAK has an Altman-Z score of -18.39. This is a bad value and indicates that VTAK is not financially healthy and even has some risk of bankruptcy.
VTAK has a Altman-Z score of -18.39. This is amonst the worse of the industry: VTAK underperforms 88.83% of its industry peers.
VTAK has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
VTAK has a better Debt to Equity ratio (0.01) than 67.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -18.39
ROIC/WACCN/A
WACC7.36%
VTAK Yearly LT Debt VS Equity VS FCFVTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

VTAK has a Current Ratio of 0.21. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
VTAK's Current ratio of 0.21 is on the low side compared to the rest of the industry. VTAK is outperformed by 96.28% of its industry peers.
VTAK has a Quick Ratio of 0.21. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.19, VTAK is doing worse than 96.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.19
VTAK Yearly Current Assets VS Current LiabilitesVTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

7

3. Growth

3.1 Past

VTAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.23%.
Looking at the last year, VTAK shows a quite strong growth in Revenue. The Revenue has grown by 9.57% in the last year.
Measured over the past years, VTAK shows a very strong growth in Revenue. The Revenue has been growing by 167.26% on average per year.
EPS 1Y (TTM)-18.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.28%
Revenue 1Y (TTM)9.57%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%74.39%

3.2 Future

The Earnings Per Share is expected to grow by 28.08% on average over the next years. This is a very strong growth
Based on estimates for the next years, VTAK will show a very strong growth in Revenue. The Revenue will grow by 312.31% on average per year.
EPS Next Y29.21%
EPS Next 2Y28.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VTAK Yearly Revenue VS EstimatesVTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTAK Yearly EPS VS EstimatesVTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 2026 -20K -40K -60K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTAK Price Earnings VS Forward Price EarningsVTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTAK Per share dataVTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

VTAK's earnings are expected to grow with 28.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.08%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTAK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATHETER PRECISION INC

NYSEARCA:VTAK (6/10/2025, 8:15:47 PM)

Premarket: 0.4686 +0.24 (+106.98%)

0.2264

+0 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners6.02%
Inst Owner Change22.39%
Ins Owners0.49%
Ins Owner Change0%
Market Cap2.49M
Analysts85.71
Price Target2.04 (801.06%)
Short Float %2.2%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.29%
Min Revenue beat(2)-53.27%
Max Revenue beat(2)-51.31%
Revenue beat(4)0
Avg Revenue beat(4)-66.02%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-67.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.08
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0.04
BVpS0.72
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.43%
ROE -292.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.02%
FCFM N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.6%
Cap/Sales 11.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.19
Altman-Z -18.39
F-Score3
WACC7.36%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.28%
EPS Next Y29.21%
EPS Next 2Y28.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.57%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%74.39%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.89%
OCF growth 3YN/A
OCF growth 5YN/A